Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Arsenal Bio

Main focus: Next-generation autologous T cell therapies

Company stage: Commercial

Diseases (gene editing): Cancer

Genome editing tool: CRISPR

Funding stage: Private

Location: South San Francisco, CA, USA


Gene editing partnerships: Bristol Myers Squibb

Arsenal Bio develops multiple proprietary technology platforms, CellFoundry™, PrimeR™ and CARchitecture™ which together with the CRISPR technology form the foundation for its next-generation therapies. While the company has yet to disclose its lead programmes, it has announced a collaboration with Bristol Myers Squibb (BMS) where the two companies will discover and develop T cell therapies for the treatment of solid tumours.



Company: Arsenal Bio
Search CRISPR Medicine